LY01005
Phase 3Small molecule
Luye Pharma Group Ltd.LY01005 is one of 50 small molecule programs targeting Breast Cancer. It is currently in Phase 3.
2
Indications
5
Total Trials
1
Active Trials
49
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Trodelvy
GileadPreclinical
Avastin
BBio-Thera Solutions
Preclinical
Nolvadex
SSan Diego Pacific Oncology & Hematology Associates
Preclinical
LY01005
Luye Pharma Group Ltd.Phase 3
Megace
Bristol-Myers SquibbPreclinical
Voltaren
NovartisPreclinical
Lupron
EEastern Cooperative Oncology Group
Preclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
Zinecard
CChildren's Oncology Group
Preclinical
Tricor
JJagotec
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Prostate Cancer4 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for LY01005. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company